We recently published 10 Double-Digit Winners You Wish You Bought Yesterday. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the last week’s top performers. Arrowhead Pharmaceuticals soared by ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, ...

Arrowhead Pharmaceuticals has a market capitalization of US$6.9b, so it's too big to fly under the radar. We'd expect to see both institutions and retail investors owning a portion of the company.

PASADENA, Calif., May 07, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: ...

Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 [email protected] Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 [email protected] www.lifesciadvisors ...

What happenedShares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) are getting pummeled in response to bad news for the company's experimental cystic fibrosis therapy. Investors unhappy about a ...

Source: Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 [email protected] Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 ...